Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Coherus BioSciences, Inc. - Common Stock
(NQ:
CHRS
)
0.7561
-0.0190 (-2.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coherus BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Top movers in Friday's after hours session
May 23, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Which stocks are moving before the opening bell on Tuesday?
May 13, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 13, 2025
Via
Benzinga
Earnings Scheduled For May 12, 2025
May 12, 2025
Via
Benzinga
Earnings Preview: Coherus BioSciences
May 09, 2025
Via
Benzinga
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
May 05, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Participate in Upcoming Investor Conferences
May 01, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
April 28, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Which stocks are moving after the closing bell on Wednesday?
April 16, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
April 14, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
April 01, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 10, 2025
March 10, 2025
Via
Benzinga
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
March 03, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
February 24, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
January 22, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
December 18, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 03, 2024
Via
Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
December 03, 2024
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
Via
Benzinga
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 03, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
November 27, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 07, 2024
Via
Benzinga
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
October 30, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
August 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.